CSIMarket
 


Iovance Biotherapeutics Inc   (IOVA)
Other Ticker:  
 
 

IOVA's Capital Expenditures Growth by Quarter and Year

Iovance Biotherapeutics Inc 's Capital Expenditures results by quarter and year




IOVA Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 3.53 3.02 7.57 23.34
III Quarter September 3.58 1.39 9.69 17.84
II Quarter June 9.52 4.58 9.62 4.98
I Quarter March 5.66 11.44 10.71 0.64
FY   22.29 20.43 37.59 46.80



IOVA Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Iovance Biotherapeutics Inc reported Capital Expenditures increase of 16.85% year on year in the fourth quarter 2023, to $ 3.53 millions, this is lower than Iovance Biotherapeutics Inc 's recent average Capital Expenditures surge of 205%.

Looking into fourth quarter 2023 results within Biotechnology & Pharmaceuticals industry 12 other companies have achieved higher Capital Expenditures growth. While Iovance Biotherapeutics Inc ' s Capital Expenditures growth of 16.85% ranks overall at the positon no. 1178 in the fourth quarter 2023.




IOVA Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 16.85 % -60.11 % -67.57 % 580.47 %
III Quarter September 157.55 % -85.66 % -45.68 % 1350.41 %
II Quarter June 107.86 % -52.39 % 93.17 % 248.25 %
I Quarter March -50.52 % 6.82 % 1573.44 % -21.95 %
FY   9.1 % -45.65 % -19.68 % 577.28 %

Financial Statements
Iovance Biotherapeutics Inc 's fourth quarter 2023 Capital Expenditures $ 3.53 millions IOVA's Income Statement
Iovance Biotherapeutics Inc 's fourth quarter 2022 Capital Expenditures $ 3.02 millions Quarterly IOVA's Income Statement
New: More IOVA's historic Capital Expenditures Growth >>


IOVA Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -1.42 % 117.27 % -21.88 % 30.83 %
III Quarter September -62.39 % -69.65 % 0.73 % 258.23 %
II Quarter June 68.2 % -59.97 % -10.18 % 678.13 %
I Quarter March 87.42 % 51.12 % -54.11 % -81.34 %
FY (Year on Year)   9.1 % -45.65 % -19.68 % 577.28 %




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #13
Healthcare Sector #138
Overall #1178

Capital Expenditures Y/Y Growth Statistics
High Average Low
744.86 % 205 % -61.76 %
(Mar 31 2021)   (Mar 31 2023)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #13
Healthcare Sector #138
Overall #1178
Capital Expenditures Y/Y Growth Statistics
High Average Low
744.86 % 205 % -61.76 %
(Mar 31 2021)   (Mar 31 2023)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Iovance Biotherapeutics Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
6853.23 % 319 % -100 %
(Sep 30 2014)  


IOVA's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Iovance Biotherapeutics Inc reported decrease in Capital Expenditures sequentially by -1.42% to $ 3.53 millions, from $ 3.58 millions released a quarter before.

Those seasonal circumstance which usually elevate IV. Quarter 2023 Capital Expenditures, were not able to rescue the IV. Quarter for the Iovance Biotherapeutics Inc , Michele Ravelli, Biotechnology & Pharmaceuticals industry observer said, he mentioned little caution conserning Iovance Biotherapeutics Inc 's direction and mentioned that average quarter on quarter Capital Expenditures growth is at 319% for the Biotechnology & Pharmaceuticals's company.

Within Biotechnology & Pharmaceuticals industry 19 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Iovance Biotherapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1114.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #20
Healthcare Sector #157
Overall #1114
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #20
Healthcare Sector #157
Overall #1114
Capital Expenditures Q/Q Growth Statistics
High Average Low
6853.23 % 319 % -100 %
(Sep 30 2014)  


IOVA's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Iovance Biotherapeutics Inc realized decrease in Capital Expenditures sequentially by -1.42% to $ 3.53 millions, from $ 3.58 millions declared in the previous reporting period.

Those seasonal circumstance which commonly elevate IV. Quarter 2023 Capital Expenditures, have not salvage the IV. Quarter for the Iovance Biotherapeutics Inc , Michele Ravelli, Biotechnology & Pharmaceuticals industry observer wrote and continued that average sequential Capital Expenditures growth is at 319% for the Biotechnology & Pharmaceuticals's company.

Within Biotechnology & Pharmaceuticals industry 19 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Iovance Biotherapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1114.


Iovance Biotherapeutics Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 22.29 $ 21.78 $ 19.59 $ 14.65 $ 20.43
Y / Y Capital Expenditures Growth (TTM) 9.13 % -12.77 % -41.11 % -61.76 % -45.64 %
Year on Year Capital Expenditures Growth Overall Ranking # 1399 # 2176 # 1624 # 1855 # 1943
Seqeuential Capital Expenditures Change (TTM) 2.33 % 11.18 % 33.75 % -28.28 % -18.21 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1178 # 1884 # 1312 # 1359 # 2071




Cumulative Capital Expenditures growth Comment
Although Iovance Biotherapeutics Inc 's Annual Capital Expenditures growth year on year were below company's average 205% , Capital Expenditures announced in the Dec 31 2023 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 9.13% year on year, from -12.77% in Sep 30 2023.

In the Healthcare sector 170 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1399, from total ranking in previous quarter at 2176.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
744.86 %
205 %
-61.76 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 13
Healthcare Sector # 171
Overall # 1399

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
744.86 %
205 %
-61.76 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 138
S&P 500 # 1178
Cumulative Capital Expenditures growth Comment
Although Iovance Biotherapeutics Inc 's Annual Capital Expenditures growth year on year were below company's average 205% , Capital Expenditures announced in the Dec 31 2023 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 9.13% year on year, from -12.77% in Sep 30 2023.

In the Healthcare sector 170 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1399, from total ranking in previous quarter at 2176.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
744.86 %
205 %
-61.76 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 13
Healthcare Sector # 171
Overall # 1399

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
744.86 %
205 %
-61.76 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 138
S&P 500 # 1178




Other Capital Expenditures Growth
Biotechnology & Pharmaceuticals Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
IOVA's Capital Expenditures Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for IOVA's Competitors
Capital Expenditures Growth for Iovance Biotherapeutics Inc 's Suppliers
Capital Expenditures Growth for IOVA's Customers

You may also want to know
IOVA's Annual Growth Rates IOVA's Profitability Ratios IOVA's Asset Turnover Ratio IOVA's Dividend Growth
IOVA's Roe IOVA's Valuation Ratios IOVA's Financial Strength Ratios IOVA's Dividend Payout Ratio
IOVA's Roa IOVA's Inventory Turnover Ratio IOVA's Growth Rates IOVA's Dividend Comparisons



Companies with similar Capital Expenditures decrease for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
Organon and Co 28.57%$ 28.571 millions
Brookdale Senior Living Inc 26.22%$ 26.219 millions
Boston Scientific Corporation25.94%$ 25.943 millions
Lifemd Inc 25.16%$ 25.162 millions
Globus Medical Inc 24.76%$ 24.760 millions
Astrazeneca Plc24.75%$ 24.748 millions
Pro dex Inc 24.36%$ 24.361 millions
Abbott Laboratories23.77%$ 23.770 millions
Cel sci Corporation21.05%$ 21.054 millions
Avanos Medical Inc 20.41%$ 20.408 millions
National Vision Holdings Inc 19.62%$ 19.623 millions
Gilead Sciences Inc 18.78%$ 18.785 millions
Butterfly Network inc 18.38%$ 18.379 millions
Protalix Biotherapeutics inc 17.37%$ 17.371 millions
Integer Holdings Corporation17.15%$ 17.145 millions
Abcellera Biologics Inc 17.04%$ 17.040 millions
Iovance Biotherapeutics Inc 16.78%$ 16.777 millions
Zoetis Inc 15.79%$ 15.789 millions
West Pharmaceutical Services Inc 14.54%$ 14.542 millions
Edwards Lifesciences Corporation14.03%$ 14.029 millions
Pulmonx Corporation13.64%$ 13.636 millions
Phibro Animal Health Corporation11.61%$ 11.610 millions
Halozyme Therapeutics Inc 10.75%$ 10.751 millions
Prestige Consumer Healthcare Inc 10.70%$ 10.704 millions
Encompass Health Corporation10.36%$ 10.362 millions
Select Medical Holdings Corp9.68%$ 9.683 millions
Owens and Minor inc9.51%$ 9.509 millions
Qiagen N v 9.02%$ 9.017 millions
Option Care Health Inc 8.98%$ 8.977 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com